Acciones de Nexalin Technology, Inc. (NXL) — ¿es un buen negocio?

Acciones de Nexalin Technology, Inc. (NXL) — ¿es un buen negocio? — InspectStocks

Cómo gana dinero

Device sales45 %
Equipment and replacement parts30 %
Licensing fees16 %

Los porcentajes de ingresos son estimaciones para year ended 2025-12-31, no cifras de un informe oficial.

Compite con

Fisher Wallace Laboratories
Flow Neuroscience
STIMNeuronetics
C
Tamaño
108,8M US$
Margen
-14,4 %
BWAYBrainsWay
A
Tamaño
394,6M US$
Margen
15,5 %

Qué vende5

Gen-1
An earlier cranial electrotherapy stimulation device used by medical professionals. Nexalin continues to service previously sold or leased devices but has paused new United States sales and marketing.
Gen-2 SYNC
A clinical-use device that delivers Nexalin’s newer 15-milliamp electrical waveform. It is under United States regulatory review and clinical development.
Gen-3 HALO
A headset being studied for physician-supervised treatment at home. A United States clinical trial for insomnia is underway.

Mostrar 2 más

Nexalin NeuroCare
Software for remote patient monitoring, doctors’ clinical workflows, collection of clinical data and virtual care.
Electrodes and patient cables
Replacement treatment components sold to medical providers using Nexalin devices.

Quién se lo compra2

Medical professionals and clinics that use Nexalin devices with patients; licensing arrangements generally involve monthly fees, and some charge by the number of treatments.
International distributors and customers that buy devices and related supplies; Nexalin recorded no international revenue in the six months ended 2026-06-30.

En qué se apoya y qué podría romperlo

De qué depende el negocio

1United States sales of new devices depend on Food and Drug Administration (FDA) clearance or approval; Nexalin’s HALO insomnia study and other clinical and regulatory work are part of that process.
2Device assembly, testing and quality checks rely mainly on third-party manufacturers.
3Clinical studies rely on outside research organizations and study sites to carry out trials and recruit participants.
4China distribution and future device registrations depend in part on Wider, which is responsible for pursuing approvals there.

Qué podría salir mal

1If clinical studies fail, take longer than planned or do not support regulatory applications, Nexalin may not obtain authorization to sell newer devices for the intended uses.
2Nexalin has limited revenue, recurring operating losses and negative operating cash flow; it says available funds are insufficient for at least twelve months from the financial statements’ issuance. Its ability to raise funds through its share-sale program is tied to continued Nasdaq listing, which was under review after a delisting determination.
3Nexalin depends on outside manufacturers and clinical research organizations. Delays, quality problems or failures to meet regulatory requirements could disrupt device production or clinical studies.

Estados financieros completos →

Sobre Nexalin Technology, Inc.

Nexalin develops devices that use electrical signals delivered through electrodes on the head to stimulate the brain. Its SYNC device is intended for clinical use, while its HALO headset is being studied for physician-supervised home use; a clinical trial for insomnia is underway. Nexalin also develops software for doctors to oversee patients remotely, manage care and collect clinical information.

Sede: Houston, Texas
Fundada en: 2010
Cotiza en: Nasdaq Capital Market
Cierre del ejercicio: December 31

Construido a partir de los propios informes de Nexalin Technology, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.

Keep exploring

The themes Nexalin Technology is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Medical Devices

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

Cómo gana dinero

Device sales45 %
Equipment and replacement parts30 %
Licensing fees16 %

Los porcentajes de ingresos son estimaciones para year ended 2025-12-31, no cifras de un informe oficial.

Compite con

Fisher Wallace Laboratories
Flow Neuroscience
STIMNeuronetics
C
Tamaño
108,8M US$
Margen
-14,4 %
BWAYBrainsWay
A
Tamaño
394,6M US$
Margen
15,5 %

Qué vende5

Gen-1
An earlier cranial electrotherapy stimulation device used by medical professionals. Nexalin continues to service previously sold or leased devices but has paused new United States sales and marketing.
Gen-2 SYNC
A clinical-use device that delivers Nexalin’s newer 15-milliamp electrical waveform. It is under United States regulatory review and clinical development.
Gen-3 HALO
A headset being studied for physician-supervised treatment at home. A United States clinical trial for insomnia is underway.

Mostrar 2 más

Nexalin NeuroCare
Software for remote patient monitoring, doctors’ clinical workflows, collection of clinical data and virtual care.
Electrodes and patient cables
Replacement treatment components sold to medical providers using Nexalin devices.

Quién se lo compra2

Medical professionals and clinics that use Nexalin devices with patients; licensing arrangements generally involve monthly fees, and some charge by the number of treatments.
International distributors and customers that buy devices and related supplies; Nexalin recorded no international revenue in the six months ended 2026-06-30.

En qué se apoya y qué podría romperlo

De qué depende el negocio

1United States sales of new devices depend on Food and Drug Administration (FDA) clearance or approval; Nexalin’s HALO insomnia study and other clinical and regulatory work are part of that process.
2Device assembly, testing and quality checks rely mainly on third-party manufacturers.
3Clinical studies rely on outside research organizations and study sites to carry out trials and recruit participants.
4China distribution and future device registrations depend in part on Wider, which is responsible for pursuing approvals there.

Qué podría salir mal

1If clinical studies fail, take longer than planned or do not support regulatory applications, Nexalin may not obtain authorization to sell newer devices for the intended uses.
2Nexalin has limited revenue, recurring operating losses and negative operating cash flow; it says available funds are insufficient for at least twelve months from the financial statements’ issuance. Its ability to raise funds through its share-sale program is tied to continued Nasdaq listing, which was under review after a delisting determination.
3Nexalin depends on outside manufacturers and clinical research organizations. Delays, quality problems or failures to meet regulatory requirements could disrupt device production or clinical studies.

Estados financieros completos →

Sobre Nexalin Technology, Inc.

Sede: Houston, Texas
Fundada en: 2010
Cotiza en: Nasdaq Capital Market
Cierre del ejercicio: December 31

Cómo gana dinero

Compite con

Qué vende5

Quién se lo compra2

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Nexalin Technology, Inc.

Keep exploring

Highest-graded in Medical Devices

Grade rose recently in Healthcare

Cómo gana dinero

Compite con

Qué vende5

Quién se lo compra2

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Nexalin Technology, Inc.

Keep exploring

Highest-graded in Medical Devices

Grade rose recently in Healthcare

Nexalin Technology, Inc.

Beneficio y valor contable — 0 de 5

Tendencia del negocio

Precio de la acción y calificación a lo largo del tiempo

Cómo gana dinero

Compite con

Qué vende5

Quién se lo compra2

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Nexalin Technology, Inc.

Keep exploring

Highest-graded in Medical Devices

Grade rose recently in Healthcare

Cómo gana dinero

Compite con

Qué vende5

Quién se lo compra2

En qué se apoya y qué podría romperlo

De qué depende el negocio

Qué podría salir mal

Sobre Nexalin Technology, Inc.

Keep exploring

Highest-graded in Medical Devices

Grade rose recently in Healthcare

Nexalin Technology, Inc.

Rentabilidad pasada

Beneficio y valor contable — 0 de 5

Tendencia del negocio

Precio de la acción y calificación a lo largo del tiempo